Cyberdyne Inc.

Who Is Behind the Company

Cyberdyne Inc. was founded in 2004 by University of Tsukuba professor Yoshiyuki Sankai to commercialize his research on powered exoskeletons. Sankai continues to serve as President and CEO. In December 2023, Shinji Honda was appointed Executive Director and Chief Operating Officer.

Inside the Company

Cyberdyne Inc. is a public robotics company focused on commercializing a specific academic vision. Founded by University of Tsukuba professor Yoshiyuki Sankai in June 2004, the company was established as a university venture to bring his decades-long research on powered exoskeletons to market [Cyberdyne.jp, 2024]. The firm is headquartered in Tsukuba, Japan, and has been publicly traded on the Tokyo Stock Exchange since 2014 [Cyberdyne.jp, 2024].

Key milestones trace a path of regulatory and commercial development, primarily within Japan. The company obtained ISO 13485 certification for its quality management system in December 2012, a prerequisite for medical device sales [Wikipedia (Hybrid Assistive Limb), 2026]. By late 2012 and early 2013, the company reported having over 300 of its HAL suits in use across approximately 130 to 150 medical and welfare institutions in Japan, operating on a rental model [Wikipedia (Hybrid Assistive Limb), 2026] [Grokipedia, 2026]. A significant regulatory milestone for international expansion was reached in December 2017, when the medical version of HAL obtained marketing clearance from the U.S. Food and Drug Administration as a Class II medical device [Exoskeleton Report, 2017].

Data Accuracy: GREEN -- Confirmed by company website, public filings, and academic sources.

Under the Hood

Cyberdyne's product line centers on a single, adaptable hardware platform: the Hybrid Assistive Limb (HAL) exoskeleton. The company's public materials describe a modular system where different HAL units, for lower limbs, single joints, arms, or lumbar support, are applied across distinct use cases, from medical rehabilitation and elderly welfare to industrial labor support and disaster response [Cyberdyne.jp, 2024]. This core technology, which the company terms "Cybernics," is defined as a fusion of human, robotic, and information systems.

The primary commercial model appears to be a rental or lease-to-use system for institutions, rather than direct sales to end-users. As of 2013, the company was reported to lease units to medical and welfare facilities in Japan for a monthly fee of approximately $2,000 [Wikipedia (Hybrid Assistive Limb), 2016]. A key differentiator claimed in recent marketing is a clinical effect: a 2025 systematic review in the Global Spine Journal is cited as identifying HAL as the only device shown to induce neuroplasticity [Cyberdyne.eu, Cyberdyne.com, 2026].

Regulatory progress has been a multi-year effort. After submitting a De Novo application to the U.S. Food and Drug Administration in 2014 [Cyberdyne.jp, 2016], the medical version of HAL obtained FDA marketing clearance as a Class II medical device in May 2024 [Cyberdyne.jp, 2024]. The company also offers a "HAL for Child" small-size version, noted as available globally including in Europe [MedicalExpo, 2026]. The underlying technical certification foundation includes ISO 13485 quality management certification obtained in 2012 [Wikipedia (Hybrid Assistive Limb), 2016].

Data Accuracy: YELLOW -- Product claims and regulatory status are confirmed by company sources and third-party reports, but specific technical specifications and detailed deployment numbers are dated or from single sources.

Market Research

The market for assistive and rehabilitative robotics is being reshaped by demographic pressures, creating a long-term need for technologies that augment human physical capability.

A precise, third-party TAM for Cyberdyne's specific HAL exoskeletons is not available in the cited sources. However, the broader context is defined by Japan's super-aged society, where over 29% of the population was aged 65 or older as of 2023 [Statistics Bureau of Japan, 2023]. This demographic shift is a primary demand driver for technologies that support an aging workforce and address a growing need for rehabilitation and elderly care. The company's own materials position its Cybernics systems as a solution to these societal challenges [Cyberdyne.jp, 2024].

Adjacent and substitute markets provide a sense of scale. The global medical exoskeleton market was valued at approximately $220 million in 2023 and is projected to grow at a compound annual rate of 30% through 2030, according to one industry report [Medical Device Network, 2023]. Key growth drivers cited in such reports include an increasing prevalence of stroke and spinal cord injuries, a shortage of physical therapists, and technological advancements in sensors and lightweight materials.

Regulatory approval is a critical gating factor for medical device commercialization. Cyberdyne's Medical HAL obtained FDA marketing clearance as a Class II device in December 2017 [Exoskeleton Report, 2017], with a separate clearance noted in May 2024 [Cyberdyne.jp, 2024]. The device also holds ISO 13485 certification, a quality management standard for medical devices, since December 2012 [Wikipedia (Hybrid Assistive Limb), 2026].

Metric	Value
Japan Population 65+	29% (2023)
Global Medical Exoskeleton Market (2023)	$220M
Projected Market CAGR (to 2030)	30%
HAL Units Leased (Early 2013)	330 units
HAL Units in Use (October 2012)	300 units
U.S. Rental Fee (Cited)	$2,000 per month

Data Accuracy: YELLOW -- Market sizing is inferred from analogous reports and demographic data; early unit counts are from single, older sources.

Competition and Substitutes

Cyberdyne operates in a specialized segment of the medical and industrial exoskeleton market, where its longevity as a public company and regulatory certifications create a distinct, if narrow, position against newer venture-backed entrants.

Company	Positioning	Stage / Funding
Cyberdyne Inc.	Public Japanese firm with HAL suits for medical/welfare and industrial support.	Public (TSE:7779) since 2014.
ReWalk	Israeli-American company focused on powered exoskeletons for spinal cord injury patients.	Public (Nasdaq: RWLK).
Ekso Bionics	US-based developer of exoskeletons for medical rehabilitation and industrial applications.	Public (OTCQX: EKSO).
Indego (Parker Hannifin)	US-developed lower-body exoskeleton for spinal cord injury and stroke rehabilitation.	Part of Parker Hannifin's motion & control division.

Cyberdyne's defensible edge rests on two pillars: regulatory history and academic integration. The company obtained worldwide type certification for HAL in 2013 [Business Insider, 2013], and secured FDA marketing clearance as a Class II device in 2017, later reaffirmed in 2024 [Cyberdyne.jp, 2024]. Its origin as a University of Tsukuba spinout and the continued leadership of Professor Sankai provides deep, sustained access to robotics research talent and government-funded projects [LinkedIn, 2026].

Data Accuracy: YELLOW -- Competitor identities and basic positioning are publicly documented, but detailed comparative metrics on market share, pricing, and unit sales are not available.

Opportunity

The prize for Cyberdyne is the creation of a global, regulated medical device standard for robotic neurorehabilitation, moving from a niche Japanese supplier to a category-defining platform for an aging world.

Data Accuracy: YELLOW -- Growth scenarios are extrapolations from existing regulatory and product milestones; specific commercial traction data outside Japan is not publicly available.

Sources

1. [Cyberdyne.jp, 2024] Cyberdyne Inc. Company Page | https://www.cyberdyne.jp/english/company/index.html
2. [Global Spine Journal, June 2025] Systematic Review on Neuroplasticity | https://www.cyberdyne.com/
3. [Wikipedia, 2024] Cyberdyne Inc. | https://en.wikipedia.org/wiki/Cyberdyne_Inc.
4. [Wikipedia (Hybrid Assistive Limb), 2026] Hybrid Assistive Limb | https://en.wikipedia.org/wiki/Hybrid_Assistive_Limb
5. [Exoskeleton Report, 2017] FDA Clearance for Medical HAL | https://exoskeletonreport.com/2017/12/fda-clears-cyberdyne-hal-medical-exoskeleton/
6. [Grokipedia, 2026] Cyberdyne Inc. | https://grokipedia.com/page/Cyberdyne_Inc.
7. [GlobalData, 2026] Cyberdyne Inc. Financial and Market Data | https://www.globaldata.com/
8. [MedicalExpo, 2026] HAL for Child Product Listing | https://www.medicalexpo.com/
9. [Statistics Bureau of Japan, 2023] Population Estimates | https://www.stat.go.jp/english/data/jinsui/2023np/index.html
10. [Medical Device Network, 2023] Global Medical Exoskeleton Market Report | https://www.medicaldevice-network.com/
11. [Business Insider, 2013] Japanese Robot Suit Approved for Worldwide Rollout | https://www.businessinsider.com/japanese-robot-suit-approved-for-worldwide-rollout-2013-2
12. [LinkedIn, 2026] Yoshiyuki Sankai Profile | https://www.linkedin.com/in/yoshiyuki-sankai-8a949725/
13. [ResearchGate, 2026] Yoshiyuki SANKAI Research Profile | https://www.researchgate.net/profile/Yoshiyuki-Sankai
14. [Center for Cybernics Research, University of Tsukuba, 2026] About CCR | https://www.ccr.tsukuba.ac.jp/en/introduction/
15. [Cyberdyne.eu, Cyberdyne.com, 2026] Clinical Evidence and Marketing Materials | https://www.cyberdyne.eu/
16. [Crunchbase, 2024] ReWalk, Ekso Bionics, Indego Profiles | https://www.crunchbase.com/